Although the poor prognosis may be associated with other non-immune mechanisms, these findings suggest that targeting the HO1/Sirt1/CD48-2B4 axis is a promising strategy for successfully treating AML. This evidence concerns the gene HMOX1 and acute myeloid leukemia.